In 2010, CEO Peter George saw the opportunity to create a new kind of pharma business: one that could get licensed and unlicensed medicines to patients all over the world, and in owning its own drugs, one that could understand the challenges from the inside.

Clinigen was formed through the merger of three successful companies: Keats Healthcare, which became Clinigen (Clinical Trial Services) CTS; Clinigen Healthcare which became Clinigen (Global Access Programs) GAP; and Clinigen, which became Clinigen (Specialty Pharmaceuticals) SP.


  • Peter George forms the Clinigen Group by bringing together Clinigen, Clinigen Healthcare and Keats Healthcare
  • Clinigen acquires its first product, Foscavir (SP) and commences Global Access Programs (GAP) supplying unlicensed medicines globally
  • Employees: 32


  • Clinigen recognized as the fastest-growing private company in the UK by the Sunday Times Virgin Fast Track 100
  • Employees: 48


  • Clinigen moves warehousing into brand new Operation Centre
  • Clinigen lists on the Alternative Investment Market (AIM) of the London Stock Exchange – the first UK healthcare company to list in London in five years
  • Employees: 72


  • Clinigen marks its first year as a public company by winning Best Newcomer at the London Stock Exchange AIM Awards
  • Clinigen wins IPO of the Year at the 2013 M&A Awards
  • Clinigen SP acquires its second product, Cardioxane
  • Employees: 101


  • Clinigen opens new, extended headquarters in Burton-on-Trent, UK
  • Clinigen SP acquires its third product, Savene
  • Clinigen SP acquires its fourth product, Ethyol
  • Peter George wins Chief Executive of the Year at 2014 European Mediscience Awards
  • Clinigen launches its new web portal, Cliniport, which allows healthcare professionals to order Clinigen GAP and SP products directly via the internet
  • Employees: 116


  • Clinigen Group acquires Idis in April 2015 to become the global leader in providing ethical compliant access to unlicensed medicines 
  • Clinigen acquires Link Healthcare in October 2015 to expand its ability to provide access to medicines for patients in the Africa, Asia, Australia regions
  • Clinigen awarded the ServiceMark accreditation by The Institute of Customer Service, in recognition of the Group’s commitment to, and achievement in customer services
  • Employees: 450


  • Launch of Japanese business, Clinigen KK, with Foscavir as our first product
  • Clinigen SP acquires its fifth product, Totect US, completing the global dexrazoxane portfolio
  • Clinigen SP continues Foscavir development with purchase of a new bag presentation
  • Clinigen SP launches Ethyol in the US in partnership with Cumberland
  • Shaun Chilton replaces Peter George as Chief Executive Officer of Clinigen Group plc
  • Employees: 530